Evidence map›Paper›PMID 26430088›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2015

Risk Stratification for Rejection and Infection after Kidney Transplantation.

Pietro E Cippà, Marc Schiesser, Henrik Ekberg, Teun van Gelder, Nicolas J Mueller, Claude A Cao, Thomas Fehr, Corrado Bernasconi

Registry-linked trialOpen access · bronzeAbstract readValidation Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07407673 (Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07407673 phase3not yet recruitingnot on this mapstarted 2027, after this paper: background citation

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study

TypeinterventionalSponsorSusanne Dam Nielsen, MD, DMScRan2027 to 2041Enrolled180ConditionsKidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant RecipientsArmsPivmecillinam, Placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 102 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Pietro E CippàDivisions of Nephrology.
Marc SchiesserVisceral and Transplantation Surgery, and.
Henrik EkbergDepartment of Nephrology and Transplantation, Skåne University Hospital, Malmö, Sweden;
Teun van GelderDepartments of Hospital Pharmacy and Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands;
Nicolas J MuellerInfectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland;
Claude A CaoPraxis Riesbach, Zurich, Switzerland;
Thomas FehrDivisions of Nephrology, Department of Internal Medicine, Cantonal Hospital Graubünden, Graubünden, Switzerland; and thomas.fehr@uzh.ch.
Corrado BernasconiLimites Medical Research, Vacallo, Switzerland.
University Hospital of Zurich · CHErasmus University Rotterdam · NLPraxis · EESkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesDefinition of individual risk profile is the first step to implement strategies to keep the delicate balance between under- and overimmunosuppression after kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used data from the Efficacy Limiting Toxicity Elimination Symphony Study (1190 patients between 2002 and 2004) to model risk of rejection and infection in the first year after kidney transplantation. External validation was performed in a study population from the Fixed-Dose Concentration-Controlled Trial (630 patients between 2003 and 2006).

resultsDespite different temporal dynamics, rejections and severe infections had similar overall incidences in the first year after transplantation (23.4% and 25.5%, respectively), and infections were the principal cause of death (43.2% of all deaths). Recipient older age, deceased donor, higher number of HLA mismatches, and high risk for cytomegalovirus disease were associated with infection; deceased donor, higher number of HLA mismatches, and immunosuppressive therapy including cyclosporin A (compared with tacrolimus), with rejection. These factors were integrated into a two-dimensional risk stratification model, which defined four risk groups: low risk for infection and rejection (30.8%), isolated risk for rejection (36.1%), isolated risk for infection (7.0%), and high risk for infection and rejection (26.1%). In internal validation, this model significantly discriminated the subgroups in terms of composite end point (low risk for infection/rejection, 24.4%; isolated risk for rejection and isolated risk for infection, 31.3%; high risk for infection/rejection, 54.4%; P<0.001), rejection episodes (isolated risk for infection and low risk for infection/rejection, 13.0%; isolated risk for rejection and high risk for infection/rejection, 24.2%; P=0.001), and infection episodes (low risk for infection/rejection and isolated risk for rejection, 12.0%; isolated risk for infection and high risk for infection/rejection, 37.6%; P<0.001). External validation confirmed the applicability of the model to an independent cohort.

conclusionsWe propose a two-dimensional risk stratification model able to disentangle the individual risk for rejection and infection in the first year after kidney transplantation. This concept can be applied to implement a personalized immunosuppressive and antimicrobial treatment approach.

Indexed as

Decision Support TechniquesImmunocompromised HostAdultAnti-Infective AgentsCommunicable DiseasesFemaleGraft RejectionHumansImmunosuppressive AgentsIncidenceKaplan-Meier EstimateKidney TransplantationMaleMiddle AgedMulticenter Studies as TopicOpportunistic InfectionsAnti-Infective AgentsImmunosuppressive Agentscause of deathcyclosporindeathhumansimmunosuppressionkidney transplantationtacrolimustransplant infectious diseasetransplant outcomestransplant recipients

Identifiers

PMID26430088
PMCPMC4670759
OpenAlexW1955294545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.